In a new publication in Cancer Immunology Research, we found that the tumor microenvironment of intrahepatic cholangiocarcinoma (ICC) - a cancer that impacts the portion of the bile duct located in the liver - is reprogrammed by chemotherapy and immunotherapy in mouse models of the disease. Importantly, ICC is sensitized by rational combinations of immunotherapy and chemotherapy that involves T cell recruitment, priming, and reactivation.